MLKL and cancer: Interestingly, it has been reported necroptotic factors are significantly reduced in numerous cancers, such as RIPK1 in neck squamous cell carcinoma (125), RIPK3 in leukemia, breast cancer, melanoma, and CRC (126, 127), and MLKL in gastric cancer, cervical squamous cell carcinoma, pancreatic adenocarcinoma and ovarian cancer (33, 128, 129), and CYLD in chronic lymphocytic leukemia, malignant melanoma and non-Hodgkin lymphoma (130–132).